author-photo

Nilanjan Ghosh

Carolinas Healthcare System
Johns Hopkins University

165

Papers

2082

Citations

Citation Trend

Filter By

Papers (165) Sort By

Journal Conference Others

Phytopharmacology of herbal biomolecules

2022
Show All
- Source
- Cite
- Save
Citations (0)
Intensive Induction Regimens after Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated with Improved Survival.

2021 European Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.

2021 Blood Advances
Show All
- Source
- Cite
- Save
Citations (0)
Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Multi-Center Analysis of Practice Patterns and Outcomes of Younger and Older Patients with Mantle Cell Lymphoma in the Rituximab Era.

2021 American Journal of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
ABCL-351: Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Very Few Interventions after Tumor Lysis Monitoring in Patients with Chronic Lymphocytic Leukemia Who Are Started on Venetoclax in the Real-World Setting– Suggests Less Intensive Monitoring Maybe Safe for Low-Risk Patients

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)